Opinion

Video

Safety of Advanced Therapies in Clinical Trials vs Real World Experience

Author(s):

Lisa J. Faia, MD ,David R. Lally, MD

Lisa J. Faia, MD asks the panel about their concerns regarding the safety of newer agents for the broad array of retinal vascular diseases, highlighting the similarities and differences between clinical trial outcomes and real-world results.

Related Videos
Ophthalmology Times: Kathryn Colby, MD, PhD, reflects on National Women Physicians Day
2 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
Related Content
Image credit: Mercy Ships
February 4th 2025

Mercy Ships delivers a lifeline for eye health in Africa’s remote communities

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

(Image credit: AdobeStock/Саша Федюк)
January 27th 2025

Optimizing the diagnosis and treatment of evaporative dry eye through meibomian gland management

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Sling Therapeutics announces topline efficacy and safety data from Phase 2b/3 LIDS trial on linsitinib
January 21st 2025

Sling Therapeutics announces topline efficacy and safety data from Phase 2b/3 LIDS trial on linsitinib

European Medicines Agency to assess semaglutide for link to NAION
January 3rd 2025

European Medicines Agency to assess semaglutide for link to NAION

© 2025 MJH Life Sciences

All rights reserved.